Search

The influence of zearalenone on blood serum protein status and the feasibility of utilizing a modified clinoptilolite and esterified glucomannan to alleviate its harmful effects was examined in two trials, 31 and 29 days long, conducted on a total of 64 pigs (32 each) 60 days old, divided into four groups, each containing 8 pigs. Control groups (K) received noncontaminated feed, while experimental groups received feed supplemented with 3.84 mg/kg in the first trial and 5.12 mg/kg of zearalenone in the second trial. Pigs in the first experimental groups (O-I) were given feed with toxin only. Modified clinoptilolite in the amount of 0.2% and esterified glucomannan in the amount of 0.1% were introduced in contaminated feed of the second (O-II) and the third experimental groups (O-III) of both trials. With the use of contaminated feed, a declining trend of the A/G ratio was observed: decrease of albumin content and increase of globulin content on account of the α globulin fraction. A decrease of the γ globulin fraction was detected at the same time. Total protein concentration was also lower. The application of adsorbents successfully alleviated harmful effects of the F-2 toxin on the affected biochemical parameters in blood serum., Uticaj zearalenona na status proteina krvnog seruma prasadi i mogućnost upotrebe modifikovanog klinoptilolita i esterifikovanog glukomanana za ublažavanje njegovih štetnih efekata ispitivan je kroz dva ogleda, u trajanju od 31 i 29 dana, izvedena na ukupno 64 prasadi (32 u svakom ogledu), 60 dana starih, podeljenih u 4 grupe, po 8 jedinki. Kontrolne grupe (K) u oba ogleda hranjene su smešom bez zearalenona, dok su eksperimentalne grupe dobijale hranu koja je sadržavala 3,84 mg/kg u prvom, odnosno, 5,12 mg/kg zearalenona u drugom ogledu. Prasad prve eksperimentalne grupe oba ogleda dobijala je hranu samo sa toksinom. Istovremeno, modifikovani klinoptilolit u količini 0,2% dodat je u hranu za prasad obe druge eksperimentalne grupe (O-II), dok je u smeši obe treće eksperimentalne grupe (O-III) bio prisutan esterifikovani glukomanan u količini od 0,1%. Upotrebom kontaminirane hrane uočen je opadajući trend A/G odnosa: smanjenje sadržaja albumina i povećanje sadržaja globulina na račun α globulinske frakcije. Istovremeno je otkriveno smanjenje koncentracije ukupnih proteina i relativne zastupljenosti γ globulinske frakcije. Primena adsorbenata uspešno je ublažila štetne efekte F-2 toksina na poremećene biohemijske parametre krvnog seruma.

Uticaj zearalenona na status proteina krvnog seruma prasadi i mogućnost upotrebe modifikovanog klinoptilolita i esterifikovanog glukomanana za ublažavanje njegovih štetnih efekata ispitivan je kroz dva ogleda, u trajanju od 31 i 29 dana, izvedena na ukupno 64 prasadi (32 u svakom ogledu), 60 dana starih, podeljenih u 4 grupe, po 8 jedinki. Kontrolne grupe (K) u oba ogleda hranjene su smešom bez zearalenona, dok su eksperimentalne grupe dobijale hranu koja je sadržavala 3,84 mg/kg u prvom, odnosno, 5,12 mg/kg zearalenona u drugom ogledu. Prasad prve eksperimentalne grupe oba ogleda dobijala je hranu samo sa toksinom. Istovremeno, modifikovani klinoptilolit u količini 0,2% dodat je u hranu za prasad obe druge eksperimentalne grupe (O-II), dok je u smeši obe treće eksperimentalne grupe (O-III) bio prisutan esterifikovani glukomanan u količini od 0,1%. Upotrebom kontaminirane hrane uočen je opadajući trend A/G odnosa: smanjenje sadržaja albumina i povećanje sadržaja globulina na račun _ globulinske frakcije. Istovremeno je otkriveno smanjenje koncentracije ukupnih proteina i relativne zastupljenosti _ globulinske frakcije. Primena adsorbenata uspešno je ublažila štetne efekte F-2 toksina na poremećene biohemijske parametre krvnog seruma., The influence of zearalenone on blood serum protein status and the feasibility of utilizing a modified clinoptilolite and esterified glucomannan to alleviate its harmful effects was examined in two trials, 31 and 29 days long, conducted on a total of 64 pigs (32 each) 60 days old, divided into four groups, each containing 8 pigs. Control groups (K) received noncontaminated feed, while experimental groups received feed supplemented with 3.84 mg/kg in the first trial and 5.12 mg/kg of zearalenone in the second trial. Pigs in the first experimental groups (O-I) were given feed with toxin only. Modified clinoptilolite in the amount of 0.2% and esterified glucomannan in the amount of 0.1% were introduced in contaminated feed of the second (O-II) and the third experimental groups (O-III) of both trials. With the use of contaminated feed, a declining trend of the A/G ratio was observed: decrease of albumin content and increase of globulin content on account of the _ globulin fraction. A decrease of the _ globulin fraction was detected at the same time. Total protein concentration was also lower. The application of adsorbents successfully alleviated harmful effects of the F-2 toxin on the affected biochemical parameters in blood serum.

Hypovolemia is represented in the clinical pathology of the dog in a high percentage. It mostly presents an accompanying syndrome in many diseased conditions (vomiting, diarrhea, sequestration, burns, cold burns, ascites periocardiac efusions, and others), while they primarily occur following acule hemorrhagia. Having in mind its diverse etiology, hypovolemia, in addition to a lack of fluids, can also be characterized by various other deficiencies (of electrolytes, proteins, albumins, carbohydrates), which presents an important factor for evaluating the condition of the patient and prescribing the adequate therapy., Na hipovolemiju relativno često nailazimo u kliničkoj patologiji pasa. Ona uglavnom predstavlja prateći simptom različitih bolesnih stanja (povraćanje prolivi, sekvestracije, opekotine, smrzotine, asci-tes, perikardijalne efuzije i slično), dok primamo nastaje nakon akutne hemoragije. S obzirom na raznoliku etiologiju, hipovolemija se osim nedostatka tečnosti može da karakteriše i različitim deficitima (elektroliti, proteini, albumini, ugljeni hidrati), što predstavlja bitan preduslov za procenu stanja pacijenta i propisivanje adekvatne terapije.